Full AUVI-Q product line now available at Walgreens locations nationwide
information provided by Walgreens
DEERFIELD, Ill. and RICHMOND, Va. (July 13, 2019) – Walgreens and kaléo, a privately-held pharmaceutical company, announced that the AUVI-q® (epinephrine injection, USP) 0.1 mg auto-injector is available at Walgreens locations nationwide. AUVI-q 0.1 mg is the first and only epinephrine auto-injector (EAI) approved by the U.S. Food and Drug Administration (FDA) for infants and toddlers weighing 16.5 to 33 pounds (7.5 to 15 kilograms).
Through this collaboration, Walgreens is the first national retail pharmacy to offer the entire AUVI-Q auto-injector product line, which also includes AUVI-Q 0.3 mg and 0.15 mg doses.
“Expanding our agreement with kaléo is one more way that Walgreens is helping lower costs for patients, increasing accessibility to care and creating a seamless experience for our customers and patients,” said Rina Shah, PharmD, group vice president of specialty and retail pharmacy at Walgreens.
All eligible patients with commercial insurance, even those with high-deductible plans, can obtain AUVI-Q at no cost. For eligible patients who do not have insurance or prescription drug coverage, kaléo may be able to support through the kaléo Cares Patient Assistance Program. Additional information on patient eligibility and the terms and conditions is available at www.auvi-q.com/get-auvi-q/.
“With approximately 1 in 13 children in the U.S. living with life-threatening food allergies*, it is critically important that parents and caregivers be able to access an epinephrine auto-injector,” said Phil Rackliffe, general manager of Allergy and Pediatrics at kaléo. “Families can get AUVI-Q 0.3 mg, 0.15 mg, and now, 0.1 mg, with a prescription, on-site at Walgreens locations nationwide.”
The Lansing Walgreens stores are located at:
- 18133 Torrence Avenue
- 3564 Ridge Road
*Lieberman, P. (2015). Anaphylaxis After Cystoscopy. The Journal of Allergy and Clinical Immunology: In Practice, 3(3), 469-470. doi:10.1016/j.jaip.2014.05.007